Synfini | Biotech/Pharma | Standout | Standout

Synfini

14 employees

Biotech/Pharma

Seed · $53.0M

Open positions (1)

Team Size14

IndustryBiotech/Pharma

Total raised

$53.0M

Last stage

Seed

Investors

JSL Health Capital

SRI Ventures

Ferocity Capital

StandoutYBacked by Y Combinator · P26

“LeBron has an agent. Why don’t you?”

— Now you have one too.

Standout.

High Water Venture Partners

Foothill Ventures

Doug Donzelli

Co-founder and Chief Executive Officer of Synfini, Inc., spun out of SRI International in 2023.

Nathan Collins

Ph.D. biotech executive with 25+ years in drug discovery; formerly Chief Strategy Officer at SRI Biosciences.

Peter Madrid

Ph.D. scientist with 17+ years in chemistry and automation technologies; formerly Head of the Applied Research group of SRI's Biosciences division.

No applications, no recruiter spam. Just the intro.

A few questions to make sure this role is the right shape for you. Two minutes.

I write the intro, send it to the founder, and handle the back-and-forth.

If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.